Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 55Endocrine 31CNS 11Gastrointestinal 9Genitourinary 8Dermatologic 8Thoracic 7Breast 7Gynecologic 6Sarcoma 4Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Other solid neoplasm 1NET 1Myeloid 1

Conditions

Multiple Myeloma 207Neoplasms, Plasma Cell 73Lymphoma 71Lymphoma, Non-Hodgkin 48Leukemia, Lymphocytic, Chronic, B-Cell 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Leukemia 37Hodgkin Disease 37Lymphoma, Follicular 36Lymphoma, Mantle-Cell 35Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 34Leukemia, Myeloid, Acute 33Lymphoma, B-Cell, Marginal Zone 32Burkitt Lymphoma 32Myelodysplastic Syndromes 31Lymphoma, Large-Cell, Immunoblastic 31Myeloproliferative Disorders 26Leukemia, Myeloid, Chronic-Phase 22Leukemia, Myeloid, Accelerated Phase 22Blast Crisis 21Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Myelomonocytic, Chronic 16Sezary Syndrome 15Mycosis Fungoides 15Lymphoma, Large-Cell, Anaplastic 15

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thyroid Neoplasms × Plasma cell × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡